Association of HO-1 and BRCA1 is critical for the maintenance of cellular homeostasis in prostate cancer by Labanca, Estefania et al.
Chromatin, Gene, and RNA Regulation
Association of HO-1 and BRCA1 Is Critical
for the Maintenance of Cellular Homeostasis in
Prostate Cancer
Estefanía Labanca1,2, Paola De Luca1, Geraldine Gueron2, Alejandra Paez2,
Cristian P. Moiola1, Cintia Massillo1, Juliana Porretti1, Jimena Giudice3, Florencia Zalazar1,
Nora Navone4, Elba Vazquez2, and Adriana De Siervi1
Abstract
Prostate cancer is the second leading cause of cancer-related
death in men worldwide. Many factors that participate in the
development of prostate cancer promote imbalance in the redox
state of the cell. Accumulation of reactive oxygen species causes
injury to cell structures, ultimately leading to cancer development.
The antioxidant enzyme heme oxygenase 1 (HMOX1/HO-1) is
responsible for the maintenance of the cellular homeostasis,
playing a critical role in the oxidative stress and the regulation
of prostate cancer development and progression. In the present
study, the transcriptional regulation of HO-1 was investigated in
prostate cancer. Interestingly, the tumor suppressor BRCA1 binds
to theHO-1 promoter and modulates HO-1, inducing its protein
levels through both the increment of its promoter activity and the
induction of its transcriptional activation. In addition, in vitro and
in vivo analyses show that BRCA1 also controls HO-1–negative
targets: MMP9, uPA, and Cyclin D1. HO-1 transcriptional regu-
lation is also modulated by oxidative and genotoxic agents.
Induction of DNA damage by mitoxantrone and etoposide
repressed HO-1 transcription, whereas hydrogen peroxide and
doxorubicin induced its expression. Xenograft studies showed
that HO-1 regulation by doxorubicin also occurs in vivo. Immu-
nofluorescence analysis revealed that BRCA1 overexpression
and/or doxorubicin exposure induced the cytoplasmic retention
of HO-1. Finally, the transcription factor NRF2 cooperates with
BRCA1 protein to activate HO-1 promoter activity. In summary,
these results show that the activation of BRCA1–NRF2/HO-1 axis
defines a new mechanism for the maintenance of the cellular
homeostasis in prostate cancer.
Implications: Oxidative and genotoxic stress converge on HO-1
transcriptional activity through the combined actions of BRCA1
and NRF2. Mol Cancer Res; 13(11); 1455–64. 2015 AACR.
Introduction
Prostate cancer is one of the most common cancers and the
second leading cause of cancer-related death in men worldwide
(1). Both environmental and genetic factors are involved in its
etiology, turning prostate cancer into a heterogeneous disease and
thus making it extremely difficult to design effective therapeutic
strategies (2). In particular, inflammation, triggered by infectious
agents or exposure to environmental factors, increases prostate
cancer tumorigenesis (3).
Oxidative stress represents an unbalanced situation between
pro-oxidative factors and oxidants controlled by multiple com-
ponents that can cause cellular damage. Reactive oxygen species
(ROS), produced during metabolism, are decisive to oxidative
stress (4). Once accumulated within the cell, ROS can damage
proteins, lipids, and DNA, contributing to a variety of human
pathogenesis, including cardiovascular, metabolic, inflammato-
ry, neurodegenerative diseases, and cancer (5). ROS also act as
secondmessengers in cell signaling being involved in awide range
of cellular processes, such as proliferation, cell-cycle arrest, and
cell death (6, 7).
The key to understand the molecular mechanisms underlying
redox regulation vests in characterizing the regulatory molecules
mediating ROS intracellular homeostasis. Tumor-suppressor
genes possess protective functions that limit tumor growth
and regulate many cellular functions (8). BRCA1 is a tumor-
suppressor gene that participates in DNA-damage repair, cell-cycle
regulation, maintenance of genomic integrity, and is involved in
numerouspathways as a transcriptional coregulator. Someof these
functions, mainly its participation in DNA-damage response,
could be associated to an essential participation of BRCA1 in
oxidative stress response. It was previously demonstrated that
BRCA1 overexpression provides resistance to different oxidant
agents and that BRCA1 induces antioxidant transcription factor
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NRF2 (NF-E2–related factor 2) activity, suggesting a novel role for
BRCA1 in protection against oxidative stress (9). Furthermore,
BRCA1 together with NRF2 preserve cells against oxidative stress
by coregulating genes containing antioxidant response elements
(ARE) on their promoter regions. In addition, through a chroma-
tin immunoprecipitation analysis combined with microarray
technology (ChIP-chip) and gene expression studies, we have
previously described that BRCA1 is a transcriptional coregulator
of genes involved in the DNA-damage response (10–12).
Heme Oxygenase 1 (HO-1), generally localized in the cyto-
plasm, is the rate-limiting enzyme in heme degradation, a pow-
erful pro-oxidative and proinflammatory agent (13). In this
context, HO-1 anti-inflammatory and antioxidative effects pro-
vide cells, tissues, and organs protection from environmental
variations. Thus, HO-1–deficient mice are more sensitive to free
radical accumulation (14, 15), and humans lacking HO-1 present
severe endothelial damage and sustained inflammation (16).
Previous studies from our laboratory showed that HO-1 is impli-
cated inprostate cancer, unveiling that endogenousHO-1 inhibits
bone-derived prostate cancer cell proliferation, invasion, and
migration in vitro and decreases tumor growth and angiogenesis
in vivo (14, 17), suggesting its antitumoral function. Despite its
importance in cellular homeostasis, the molecular mechanisms
underlying the transcriptional regulation of HO-1 are still poorly
understood (18).
In this study, we provide an unprecedented mechanism that
regulates HO-1 transcription. We demonstrated that BRCA1 reg-
ulates HO-1 expression in prostate cancer cells. Furthermore, we
determine that different oxidative stress or DNA-damage agents,
such as mitoxantrone and etoposide, impair HO-1 transcription.
This study describes a novel mechanism forHO-1 transcriptional
regulation mediated by BRCA1, shedding light into its role in the
maintenance of the cellular homeostasis.
Materials and Methods
Cell culture and treatments
PC3 (ATCC: CRL-1435), LNCaP (ATCC: CRL-1740), 22Rv1
(ATCC: CRL-2505), and C4-2 (derived from LNCaP) cells were
routinely cultured in RPMI 1640 (Invitrogen) supplemented with
10%FBS. PC3 stable cell lines (pcDNA3, pcDNA3BRCA1, shRNA
Scramble, and shRNA BRCA1) and LNCaP stable cell lines
(shRNA Scramble and shRNA BRCA1) were previously described
(11, 19). Doxorubicin (Rontag S.A.) was used at a final concen-
tration of 1 mmol/L and 2 mmol/L for 0, 6, 18, and 24 hours.
Mitoxantrone (Micraleve; Ivax, Argentina) was used at final con-
centration of 1 mmol/L for 24 hours. Etoposide (Sigma-Aldrich)
was used at final concentration of 5 mmol/L for 24 hours.
Methotrexate (Ervemin, Ivax, Argentina) was used at final
concentration of 200 mmol/L for 24 hours. Hydrogen peroxide
(ParaFarm, Saporiti, Argentina) was used at final concentration
of 400 mmol/L for 6 hours.
Plasmids
BRCA1 expression vector (pcDNA3 BRCA1) has been previ-
ously described in ref. 20. shRNA Scramble and shRNA
BRCA1 vectors were from Upstate. hHO4.9-luc (HO1-luc) and
hHO4.9_M2-luc (mutHO1-luc) were previously described (17).
pcDNA3 NRF2 and pcDNA3 NRF2 dominant-negative (DN)
vectors were kindly provided by Dr. Omar Coso (IFIBYNE, Uni-
versity of Buenos Aires, Argentina).
Immunoblot analysis
Prostate cancer cells were lysed and immunoblotted as previ-
ously described (17) using antibodies against HO-1 (Stressgen
Biotechnologies, Corp.), b-actin (Santa Cruz Biotechnology), and
BRCA1 protein, gently provided by Dr. Kevin Gardner (NCI-NIH;
ref. 10). Reactions were detected by horseradish peroxidase–
conjugated secondary antibodies and enhanced chemilumines-
cence (Pierce) following the manufacturer's directions. Protein
quantitation was performed using Image J 1.41 software (http://
rsb.info.nih.gov, NIH).
Luciferase reporter assay
PC3 cells were transiently transfected by the polyethylenimine
method with 1 mg of each plasmid. After transfection cells were
maintained in complete medium for 48 hours, they were har-
vested and lysed on Reporter Lysis Buffer with 40 mL of Steady
Glomax Luciferase System (Promega). Luciferase activity was
determined in Luminometer (Glomax Multi Detection System;
Promega), and data were normalized to total protein determined
by the Bradford assay.
Human prostate cancer xenografts
Xenograft experiments were performed as previously described
(11). All animal experiments were conducted in accordance with
accepted standards of animal care and were approved by the
Institutional Animal Care and Use Committee (IACUC) of the
University of Buenos Aires (http://users.df.uba.ar/zeke/). Briefly,
6-week-old male nu/nu mice, each weighting at least 20 g, were
housed under pathogen-free conditions. Mice were randomized
into two groups: shRNA Scramble or shRNA BRCA1. Tumor cells
(4.8  106 cells) were inoculated s.c. into the right flank of the
mice. After 14 days, when the tumors reached approximately 50
mm3, mice were randomly distributed into two groups (5 mice
per group) and injected i.p. with doxorubicin (8mg/kgmouse). A
second injection was administered after 9 days, and themice were
sacrificed 24 hours after the last injection. RNA was isolated from
tumors as described (17).
RNA isolation, cDNA synthesis, and quantitative PCR
Prostate cancer cells were exposed to different treatments, and
total RNAwas isolated using TriReagent (Genbiotech). cDNAwas
retrotranscribed from 2 mg of RNA using RevertAid First Strand
(Fermentas). Real-time PCR (qPCR) was performed as previously
described (21) using Taq Polymerase (Invitrogen) and SYBR
Green as fluorescent dye for amplified product detection in a
DNA Engine Opticon (MJ Research, BioRad). Each PCR was done
in duplicate, and the experiment was repeated at least thrice. Data
were analyzed by Opticon-3 software and normalized to b-actin
(ACTB). Errors were calculated as previously described (10).
Primers sequences were previously described: BRCA1 (10),
HO-1, MMP9 (17), uPA, Cyclin D1, and ACTB (21).
Chromatin immunoprecipitation
Chromatin immunoprecipitation (ChIP) was performed from
PC3 cells as previously described (12) using anti-BRCA1 (10)
antibodies. Anti-Gal4 antibody from Santa Cruz Biotechnologies
was used as nonspecific control. ChIP-DNA was amplified by
qPCR using primers mapping at 9 Kb and 4 Kb upstream from
HO-1 transcription start site (TSS), or 0.2 Kb upstream from
b-globin. Primer sequences were as follows: ChIP HO-1 –9 kb
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FW 50CCCTGCTGAGTAATCCTTTCCCGA30 and RV 50ATGTCC-
CGACTCCAGACTCCA30; ChIP HO-1 –4 kb FW 50GGTAGGCA-
GGAGGAAGTG30 and RV 50AGAGATGTGAAGCATAAGAAGG30;
b-globin FW 50TTTGCAGCCTCACCTTCTTT30 and RV 50TGGG-
GGATATTATGAAGGGC30. Fold enrichment was calculated
normalizing data to input as previously described (12).
Immunofluorescence experiments
Immunofluorescence experimentswere performed as previous-
ly described (21). Briefly, cells were seeded in 6-well plate at a
density of 1  106 cells per well on coverslips overnight. After
treatments, cells were fixed in ice-cold methanol, permeabilized
with 0.5% Triton X-100/PBS, washed, and blocked. Cells were
incubated overnight with primary antibodies and after 3 to 4
washes were incubated with fluorescent secondary antibodies.
Negative controls were carried out using PBS instead of primary
antibodies. Cells were washed, mounted in FluorSave Reagent
(MerckMillipore), and imaged by confocal laser scanningmicros-
copy with an Olympus Fluoview FV 1000 microscope. An Olym-
pus 60 1.20 N.A. UPLAN APO water immersion objective was
used. Excitation and emission filter for Alexa Fluor-647 were as
follow: excitation, 650 nm; emission, band-pass (BP) 665 nm.
All the images were processed for presentation applying exactly
the same parameters using ImageJ (http://rsb.info.nih.gov, NIH).
Background of each channel was subtracted, a median filter
(radius: 1 pixel) was applied. Quantitative microscopy measure-
mentswere performed in individual cells using ImageJ (http://rsb.
info.nih.gov, NIH) as previously described (21–23). Briefly, the
signal of the secondary antibody alone was subtracted for all the
HO-1 images. Segmentation was manually performed for each
cell using the HO-1 (green) images, and HO-1 signal ("HO-1
cell") was measured as well as the cell size; therefore, HO-1
fluorescence was normalized to the cell size. The nucleus was
segmented using DAPI signal (blue), and HO-1 signal was mea-
sured within this region obtaining "HO-1 nucleus." The ratio
"HO-1 cell"/"HO-1 nucleus" was then calculated as an estimation
of HO-1 intracellular distribution. This "internal calibration"
approach removes the influence of the amplifier gain and the
zoom factor for each image acquisition condition (24). Results are
shown as mean () SEM of "n" cells.
Statistical analysis
All results are given as mean () SD of "n" separate indepen-
dent experiments unless stated otherwise. Student tests were used
to ascertain statistical significance with a threshold of P < 0.05.
Comparisons for in vivo experiments were made with one-way
ANOVA followed by the Dunnett test, with P < 0.05 as the
criterion for statistical significance.
Results
Prostate cancer cells express different levels of HO-1
Wefirst assessedBRCA1andHO-1 expression levels in different
human prostate cancer cell lines: PC3 (androgen receptor nega-
tive), LNCaP (androgen receptor positive), 22Rv1 (androgen
receptor positive), and C4-2 (androgen receptor positive, derived
from LNCaP after grown in castratedmice, androgen insensitive).
LNCaP cells showed the highest levels of HO-1 and BRCA1,
whereas the lowest expression for both proteins was found in
PC3 cells (Fig. 1A). As we previously reported, HO-1 expression
was higher in androgen-sensitive cell lines (17).
BRCA1 induces HO-1 transcription in prostate cancer cells
We previously reported that BRCA1 induces the expression of
genes involved in stress response and resistance to genotoxic
agents in prostate cancer (10–12, 19). In addition, it is known
that BRCA1 protects cells against oxidative stress upregulating
genes carrying ARE (9). Given that HO-1 contains ARE sites in its
promoter region and participates in the maintenance of the
cellular homeostasis by reducing oxidative injury, we investigated
whether BRCA1 could regulate HO-1 expression in prostate
cancer cell lines.
We generated BRCA1-overexpressing or depleted stable-trans-
fected PC3 cell lines and BRCA1-depleted stable LNCaP cells and
assessed HO-1 protein and mRNA levels (Fig. 1B–D). BRCA1-
overexpressing PC3 cells displayed increased HO-1 protein and
mRNA levels compared with control cells (Fig. 1B and C). Con-
sistently, HO-1 induction was abolished after BRCA1 depletion
by shRNA in PC3 and LNCaP cells (Fig. 1C and D). Furthermore,
we determined HO-1 expression in BRCA1-overexpressing tran-
siently transfected C4-2 and 22v1 cells by RT-qPCR. HO-1mRNA
levels were also induced by BRCA1 overexpression in all cell lines
tested (Fig. 1B). Given that BRCA1 regulates HO-1 expression in
all the prostate cancer cell lines tested, we choose PC3 cells for the
following experiments performed.
To elucidate whether BRCA1 regulated HO-1 promoter activ-
ity, we carried out reporter assays by cotransfecting PC3 cells
with BRCA1 expression or control vectors and a construct
containing the 4.9 kb promoter region of the human wild-type
HO-1 gene upstream of the luciferase reporter gene (HO1-luc;
ref. 17). HO-1 luciferase reporter assays showed that BRCA1
overexpression significantly induced HO-1 promoter activity in
PC3 cells (Fig. 1E). Altogether, these results demonstrate that
BRCA1 regulates HO-1 expression at the transcription level in
prostate cancer cell lines.
BRCA1 protein binds the HO-1 promoter
To further investigate HO-1 regulation by BRCA1, we per-
formed BRCA1 ChIP in PC3 cells and found that BRCA1 binds
the HO-1 promoter at 4 Kb and 9 Kb upstream of the HO-1 TSS
(Fig. 1F). These results show that BRCA1 associates with HO-1
promoter in PC3 cells.
BRCA1 switches off negative targets of HO-1 in prostate cancer
We have previously shown that HO-1 has the ability to asso-
ciate with promoters of genes relevant to prostate carcinogenesis,
such as uPA, MMP9, and cyclin D1 (21). Moreover, HO-1 induc-
tion in prostate cancer impairs MMP9 expression and activity
(17). To investigate whether BRCA1 modulates HO-1 function,
we assessed the mRNA levels of HO-1 target genes under BRCA1
modulation. BRCA1 overexpression in PC3 cells turned off down-
stream targets of HO-1: MMP9, uPA, and Cyclin D1 (Fig. 2A).
Accordingly, uPA and Cyclin D1 expression levels were induced
in BRCA1-depleted PC3 cells (Fig. 2B). No significant changes
were observed at MMP9 expression levels after BRCA1 depletion
(Fig. 2B).
Furthermore, we developed a xenograftmodel in nu/numice by
injection of BRCA1-depleted PC3 (shRNABRCA1) or control cells
(shRNA Scramble; ref. 11). We previously demonstrated that
BRCA1 depletion increased tumor growth rate (11). To determine
whether BRCA1modulates HO-1 expression and function in vivo,
we analyzed HO-1 and the expression levels of its target genes by
RT-qPCR. Even though no significant differences were detected in
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Figure 1.
BRCA1 upregulates HO-1 expression in prostate cancer cell lines. A, HO-1, BRCA1, and b-actin expression was determined in PC3, LNCaP, 22Rv1, and C4-2 cell
lines by Western blot. Quantification and normalization to b-actin protein levels and PC3 cells are shown under each band. One representative
experiment from two biologic replicates is shown. B, HO-1 mRNA levels were analyzed by RT-qPCR in PC3, C4-2, and 22Rv1 cells transfected with pcDNA3
BRCA1 plasmid or control (pcDNA3). Data were normalized to b-actin and pcDNA3-transfected cells. One representative from two independent experiments
is shown ( , P < 0.05). C, PC3 (pcDNA3, pcDNA3 BRCA1, shRNA Scramble, and shRNA BRCA1) and LNCaP (shRNA Scramble and shRNA BRCA1) stable cell
lines were generated, and HO-1, BRCA1, and b-actin expression was determined by Western blot. Numbers below bands show quantitation using ImageJ
software. Data were normalized to b-actin and control cells. One representative of two independent experiments is shown. D, HO-1 mRNA levels were
analyzed by RT-qPCR in LNCaP shRNA Scramble and LNCaP shRNA BRCA1 stable cells lines. Data were normalized to b-actin and control cells. One
representative from two independent experiments is shown ( , P < 0.05). E, reporter assay in PC3 cells transfected with HO-1 luciferase plasmid. After
transfection, cells were maintained in complete medium, lysed, and luciferase activity was assayed. Data were normalized to protein values and control cells.
Mean  SD from three biologic replicates is shown ( , P < 0.05). F, ChIP analysis using BRCA1-specific or non-specific (GAL4) antibodies in PC3 cells was
performed. DNA-ChIP was analyzed by qPCR using primers located at 9 Kb and 4 Kb upstream from HO-1 TSS or 0.2 Kb upstream from b-globin TSS.
Fold enrichment was calculated normalizing data to input.
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Figure 2.
BRCA1 represses HO-1–negative target genes in prostate cancer. A, mRNA expression levels for the indicated genes were analyzed by RT-qPCR in
PC3 pcDNA3 and pcDNA3 BRCA1 stable cell lines. Data were normalized to b-actin and control. One representative experiment from three biologic replicates
is shown ( , P < 0.05). B, mRNA expression levels for the indicated genes were analyzed by RT-qPCR in PC3 shRNA Scramble and shRNA BRCA1 stable
cell lines. Data were normalized to b-actin and control. One representative experiment from three biologic replicates is shown ( , P < 0.05). C, harvested
tumors derived from PC3 shRNA Scramble and shRNA BRCA1 cells were snap-frozen in liquid nitrogen and subsequently processed for RNA isolation. mRNA
expression levels for the indicated genes were analyzed by RT-qPCR. Data were normalized to b-actin and control. Bars represent mean  SD from five
biologic independent xenografts ( , P < 0.05).
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HO-1 expression levels, BRCA1-depleted tumors showed highly
increased expression of MMP9, uPA, and Cyclin D1 (Fig. 2C).
Altogether, our results show that BRCA1 reduces the expression
levels of HO-1 downstream targets both in vitro and in vivo.
Genotoxic and cytotoxic agents modulate HO-1 transcription
BRCA1 participates in the DNA-damage response caused by
genotoxic agents through specific gene-target regulation (11). To
assess the involvement of the BRCA1/HO-1 axis in the oxidative
stress response in prostate cancer, we assessed HO-1 regulation in
response to a variety of genotoxic and oxidizing agents. HO-1
levelsweredeterminedbyRT-qPCRafter exposureof PC3 cells to a
panel of drugs: group 1, DNA-damage inducers: mitoxantrone
and etoposide; group 2, oxidative stress inducers: hydrogen
peroxide; group 3, DNA-damage/oxidative stress inducers: doxo-
rubicin; and group 4, other effect inducers: methotrexate. The
results displayed in Fig. 3A show that HO-1 transcription was
significantly downregulated by group 1 agents, upregulated by
groups 2 and 3 agents, whereas no significant variation was
observed for group 4 drugs.
We subsequently focused our studies in the effect of doxoru-
bicin onHO-1 transcription. Previous findings of our laboratory
demonstrated that this drug upregulates BRCA1 expression (10).
We performed a time–response treatment by exposing PC3
cells to this agent and then determined HO-1 and BRCA1mRNA
levels using RT-qPCR. We found that HO-1 and BRCA1 expres-
sion levels were induced after 18-hour doxorubicin treatment
(Fig. 3B).
To examine HO-1 modulation after doxorubicin treatment in
vivo, nu/numice were injected s.c. with PC3 cells and, 14 days after
injection, mice were randomly distributed into two groups (5
mice per group) and administrated i.p. doxorubicin or vehicle.
Tumors were excised, and RT-qPCR analysis revealed a significant
induction of HO-1 transcription in doxorubicin-treated xeno-
grafts (Fig. 3C). These results demonstrate that doxorubicin
induces HO-1 expression in vivo.
BRCA1 and/or doxorubicin increase HO-1 expression and
cytoplasmic retention
Since nuclear localization of HO-1 has been reported in pros-
tate cancer (17, 25, 26), we investigated BRCA1 and/or doxoru-
bicin effects on HO-1 subcellular localization by immunofluo-
rescence analysis.
Although some HO-1 nuclear signal was found in PC3 cells,
it was mainly detected in the cytoplasmic compartment
(Fig. 4A, control cells). HO-1 nuclear signal/HO-1 total signal
ratio was measured in individual cells (Fig. 4B), revealing that
BRCA1 overexpression induces HO-1 cytoplasmic retention
(Fig. 4A and C).
Doxorubicin treatment also causes HO-1 retention in the
cytoplasm of control cells as well as under BRCA1-induced con-
ditions (Figs. 4A and C).
Figure 3.
HO-1 transcription is modulated in
response to genotoxic and cytotoxic
agents. A, HO-1 expression was
analyzed by RT-qPCR after PC3 cells
exposure to: group 1 ¼ DNA-damage
agents: mitoxantrone (Mito: 1 mmol/L,
24 hours) and etoposide (Eto:
5 mmol/L, 24 hours); group
2 ¼ oxidative stress agents: hydrogen
peroxide (H2O2: 400 mmol/L, 6 hours);
group 3 ¼ combined effects agents:
doxorubicin (Doxo: 2 mmol/L,
24 hours); group 4 ¼ other effects
agents: methotrexate (MTX:
200 mmol/L, 24 hours). Data were
normalized to b-actin and vehicle
(DMSO). One representative from two
independent experiments is shown
( , P < 0.05). B, BRCA1 and HO-1
RT-qPCR from PC3 cells treated with
doxorubicin (1 mmol/L) for the
indicated times (0 to 24 hours). Data
were normalized to b-actin and
control (DMSO). One representative
from three independent experiments
is shown (, P < 0.05). C, prostate
cancer xenografts derived from PC3
cells were grown in nude mice. Mice
were injected i.p. with doxorubicin
(Doxo; 8 mg doxorubicin/kg mouse)
or vehicle (control; DMSO) on days 14
and 24. Mice were sacrificed 24 hours
after the last injection, and RT-qPCR
analysis of HO-1was carried out. Graph
bar represents the mean  SD from
five tumors. Data were normalized to
b-actin and control (, P < 0.05).
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In addition, quantification of HO-1 total signal confirms that
BRCA1 overexpression results in a significant increase in HO-1
levels, which are even significantly higher when cells are exposed
to doxorubicin (Fig. 4D).
BRCA1 modulates HO-1 transcription through coregulation
with NRF2
It has long been known that the transcription factor NRF2 is a
transcription regulator ofHO-1 (18). Thus, we hypothesized that
BRCA1 protein and NRF2 could coregulate HO-1 transcription.
For this purpose, we assessedHO-1mRNA levels in PC3 cells after
NRF2 modulation. NRF2 overexpression significantly induced
HO-1 mRNA levels and promoter activity in these cells (Fig. 5A
and B). We previously demonstrated that BRCA1 regulates gene
expression through the direct interaction with transcription
factors (10, 11). Considering that both, BRCA1 and NRF2, are
involved in HO-1 regulation, we assessed theHO-1 transcription-
al coregulation by these factors using reporter assays. As shown
in Fig. 5C, BRCA1 and NRF2 overexpression resulted in a higher
activation of the HO-1 promoter, compared with either of them
alone.
Consistently, enhanced HO-1 promoter activity by BRCA1
overexpressionwas lostwhen theNRF2DNconstructwas cotrans-
fected together with BRCA1 expression vector and HO1-luc
reporter plasmid (Fig. 5C). These results provide evidence that
HO-1 transcription activation by BRCA1 is NRF2 dependent.
Furthermore, we performed reporter assays using an HO-1
promoter construct carrying a mutation in the MARE site (Maf
recognition element site; mutHO1-luc). HO-1 promoter activity
induction by BRCA1, NRF2, and the combination of both factors
was completely abolished when the MARE site atHO-1 promoter
was mutated (Fig. 5C). These results suggest that antioxidant
response elements are required for HO-1 modulation by BRCA1
and NRF2.
Finally, we analyzed HO-1 promoter activity after BRCA1
depletion (Fig. 5D).We found that BRCA1 depletion significantly
reduced HO-1 promoter activity. Interestingly, BRCA1 depletion
completely abrogated transcriptional induction ofHO-1 byNRF2
Figure 4.
BRCA1 overexpression and/or doxorubicin treatment induces HO-1 expression and favors its cytoplasmic localization in PC3 cells. A, PC3 cells transiently
transfected with BRCA1 overexpression or control empty vector were treated with doxorubicin (Doxo; 2 mmol/L, 24 hours) or vehicle. Cells were fixed in
methanol, and HO-1 distribution was analyzed by confocal fluorescence microscopy (green: Alexa Fluor 647). Nuclei were stained using DAPI (blue). B, cell outline
and whole-cell nuclear segmentation to calculate nuclear HO-1/total HO-1 ratio in a single-cell analysis. C, quantification of nuclear to cellular HO-1 signal
relation ( , P < 0.05, respect to control). D, total HO-1 signal quantification ( , P < 0.05, respect to control).
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(Fig. 5D). Altogether, these results suggest that BRCA1 and NRF2
proteins are recruited to MARE sites in HO-1 promoter activating
its transcription in PC3 cell line.
Discussion
Prostate cancer continues to be a worldwide problem in the
area of health, being the second cause of death by cancer in men
(1). Many of the factors that take part in the development of
prostate cancer, such as age, genetic predisposition, environmen-
tal factors, diet, and exposure to infectious agents or androgens,
promote imbalance in the redox state of the cell (27), leading to
tissue remodeling and proliferation. Chronic and acute inflam-
mation generates ROS that damage cellular structures.
HO-1 plays a crucial role in the maintenance of cellular
homeostasis and in the control of inflammation and oxidative
stress. Based on this, we investigated the mechanisms of tran-
scriptional regulation of HO-1, which still remain unknown.
Because of the essential role of BRCA1 in the maintenance of
genomic integrity, we focused our work in the potential tran-
scriptional regulation of HO-1 by BRCA1. We found that BRCA1
induces HO-1 expression in prostate cancer cell lines and mod-
ulates its function through transcriptional regulation of its target
genes: uPA, MMP9, and Cyclin D1. Further, we demonstrate for
the first time that BRCA1 associates with HO-1 promoter at 4 Kb
and 9 Kb upstream of the HO-1 TSS.
Herein, we propose that BRCA1 could fulfill its protective role
counteracting oxidative stress through the transcriptional regula-
tion of HO-1. Thus, the results exposed here support a new
function for BRCA1 in tumor suppression of prostate cancer: the
maintenance of the cellular homeostasis through the transcrip-
tional activation of HO-1.
Previously, Bae and colleagues (9) demonstrated that BRCA1
prevents DNA damage due to ionizing radiations and other
sources by ROS detoxification. These evidences are in line with
the results presented herewhereHO-1 expression ismodulated by
Figure 5.
BRCA1, together with NRF2, induces HO-1 promoter activity in prostate cancer cells, and MARE site in HO-1 promoter is required for this regulation. A, HO-1 mRNA
levels were analyzed by RT-qPCR in PC3 pcDNA3 and PC3 pcDNA3 NRF2 transient transfected cells. Data were normalized to b-actin and control. One
representative from at least three independent experiments is shown ( , P < 0.05). B, PC3 cells were cotransfected with the HO-1 luciferase plasmid and
pcDNA3 NRF2 or empty vector (pcDNA3). Cells were maintained in complete medium and 48 hours after transfection were lysed, and luciferase activity was
assayed. Data were normalized to protein values and control. One representative from at least three independent experiments is shown ( , P < 0.05). C, PC3
transiently expressing HO1-luc reporter plasmid or the variant containing the MARE site mutated was cotransfected with BRCA1 overexpression vector (pcDNA3
BRCA1) and NRF2 overexpression vector (pcDNA3 NRF2) or NRF2 DN vector (pcDNA3 NRF2 DN) or control empty vector (pcDNA3). Cells were harvested 48 hours
after transfection, and luciferase activity was measured. Data were normalized to protein values and control. Mean  SD from three biologic independent
experiments is shown ( , P <0.05). D, PC3 cellswere cotransfected with HO1-luc reporter plasmid and pcDNA3NRF2 or pcDNA3 empty vector, and shRNABRCA1 or
shRNA Scramble vectors. Cells were harvested 48 hours after transfection, and luciferase activity was measured. Transfections were performed in triplicate in
at least three biologic independent experiments ( , P < 0.05).
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diverse genotoxic and oxidating agents, as well as by the tran-
scriptional regulator BRCA1 (9). HO-1 regulation by DNA-dam-
age agents and/or oxidative stress inducers, herein stated, would
affect the defense mechanism to maintain cellular homeostasis.
The differential modulation obtained when cells are exposed
either to DNA-damage inducers or to oxidative stress agents
suggests the existence of a dual role for BRCA1. We speculate
that BRCA1 is primarily recruited to HO-1 promoter under oxi-
dative injury, but under DNA damage, it becomes majorly
recruited to other promoters different than the HO-1 gene.
In particular, we demonstrate that doxorubicin increases HO-1
levels inprostate cancer xenografts.Given that doxorubicin is used
in chemotherapy for the treatment of several types of cancer, our
results will contribute with additional evidence for HO-1's poten-
tiality as a therapeutic target. Future studies will determine the
relevance of thesefindings in prostate cancer therapy or prognosis.
HO-1 role in the DNA-damage response has been previously
reported (28). These authors showed that HO-1 modulates DNA
repair through carbon monoxide. In this analysis, the authors
described a new function for HO-1, modulating ATM protein
expression. In addition, we previously reported that BRCA1 also
regulates ATM expression (12). Altogether, the results presented
here show for the first time a new BRCA1/HO-1/ATM axis
regulation.
Regarding HO-1 cellular localization, previous works from our
laboratory reported that HO-1 nuclear translocation is associated
with prostate cancer (25). In this work, we demonstrated that
BRCA1-overexpressing cells and/or cells exposed to doxorubicin
do not display greater HO-1 translocation to the nucleus com-
paredwith cells with control levels of BRCA1 and cells that are not
exposed to the chemotherapeutic agent. HO-1 is active at the
cytoplasm (26, 29); therefore, the observed cytoplasmic HO-1
retention after BRCA1 overexpression and/or doxorubicin expo-
sure could be associated with HO-1 function such as cellular
homeostasis modulation.
To further our analysis on the HO-1/BRCA1/NRF2 axis, we
used cBioPortal (30, 31) to mine genomic datasets of human
prostate tumors. The cross-cancer alteration summary for BRCA1,
HMOX1 (HO-1), and NFE2L2 (NRF2) displays no significant
pattern for mutations, amplifications, deletions, or multiple
alterations (Supplementary Fig. S1A). Of the nine datasets pres-
ent, only one, the MSKCC-Prostate Oncogenome Project dataset
(103 clinical human samples of prostate adenocarcinoma vs.
normal gland), showed a statistically significant tendency
toward co-occurrence of alterations in the gene pair BRCA1-NRF2
(P ¼ 0.01). Regarding mRNA coexpression of HO-1/BRCA1/
NRF2, results display some discrepancies in Pearson correlation
scores. While in the Broad/Cornell 2012 & 2013 studies, BRCA1/
NRF2 and HO-1/NRF2 pairs show a high mRNA coexpression
(Pearson¼ 0.56 and 0.59, respectively; Supplementary Fig. S1B),
in the MSKCC study, HO-1/NRF2 mRNA coexpression is listed
among the highest expression correlation pair but with a Pearson
score of –0.44 (Supplementary Fig. S1C). mRNA expression z-
scores versus normal for the same pair also rank among the list of
highest expression correlation with a similar Pearson correlation
(–0.47; Supplementary Fig. S1D). Interestingly and in line with
the work presented here, the HO-1/BRCA1 pair exhibits a high
expression correlation when studying mRNA expression outliers
(Pearson correlation 0.35; Supplementary Fig. S1E). In summary,
we establish a new function for BRCA1 in the survival and fate of
prostate tumor cells, orchestrating oxidative stress and mounting
a transcriptional regulatory machinery commanding HO-1 tran-
scriptional activation.
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